Compare NICE & BIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NICE | BIO |
|---|---|---|
| Founded | 1986 | 1952 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Laboratory Analytical Instruments |
| Sector | Technology | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.4B | 7.2B |
| IPO Year | N/A | N/A |
| Metric | NICE | BIO |
|---|---|---|
| Price | $110.90 | $270.07 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 4 |
| Target Price | $156.07 | ★ $358.50 |
| AVG Volume (30 Days) | ★ 1.1M | 289.4K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $10.04 | $2.31 |
| Revenue Next Year | $9.72 | $3.10 |
| P/E Ratio | $11.21 | ★ $9.72 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $94.65 | $211.43 |
| 52 Week High | $180.61 | $343.12 |
| Indicator | NICE | BIO |
|---|---|---|
| Relative Strength Index (RSI) | 53.65 | 36.78 |
| Support Level | $104.02 | $266.71 |
| Resistance Level | $114.45 | $290.01 |
| Average True Range (ATR) | 5.03 | 9.45 |
| MACD | 0.97 | -1.37 |
| Stochastic Oscillator | 74.42 | 34.48 |
Nice is an enterprise software company that serves the customer engagement and financial crime and compliance markets. Software is deployed primarily on the cloud, but also on premises. Within customer engagement, Nice's CXone is the leading CCaaS platform providing solutions such as call routing, interactive voice response, digital self-service, and workforce engagement management. Within financial crime and compliance, Nice offers risk and investigation management, fraud prevention, anti-money-laundering, and compliance solutions.
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.